Possibilities of immunogistochemical investigation in respons prognosis to treatment and modification of treatment activities at luminal breast cancer (literature review).
DOI:
https://doi.org/10.26641/2307-0404.2017.4.117658Ключевые слова:
breast cancer, immunohistochemical investigation, hormonal therapyАннотация
This article is concerned with both standard (estrogen and progesterone receptors, Her2/neu and Ki67) immunohistochemical investigation in hormonal therapy tactics decision for luminal breast cancer and additional investigation of such hormonal sensibility marker as cyclin D1, Bcl-2, AIB1, Her1, p53, IGF-IR, COX-2 and its influence on modified hormonal therapy impact on tumor. It was shown that tumors expressing Her2/neu, AIB1, Her1, p53 or tumors, that have more than 30% expression of cyclin D1 are resistant to antiestrogen but sensible to aromatase inhibitors. IGF-IR and COX-2 tumors are resistant to aromatase inhibitors. Metformin usage for IGF-IR hyperexpression and oxygenase selective inhibitors for COX-2 expression promotes sensibility increase for aromatase inhibitors.
Библиографические ссылки
Antonenkova NN. [Inactivation of estrogen synthetase with aromazine for the purpose of irreversible blockade of an estrogens synthesis for operable patients with breast cancer]. Vestnik VGMU. 2007;6(3):1-11. Russian.
Baryshnikov AU, Stepanova EV. [Problems of the drug resistance]. III Russian Oncology Conference. 1999 29 nov. - 1 decem.; Sankt-Peterbur, Russian. Available from: http://www.rosoncoweb.ru/library/congress/ru/03/02.php. Russian.
Bezruk NG. [Immediate and long-term results of breast cancer conservating treatment T≤3cmN0M0]. [dissertation].Donetsk, 1999;19. Ukrainian.
Borisova EI. [Everolimus (Athenitor) in the treatment of breast cancer]. Effective pharmacotherapy: oncology, hematology and radiology. 2012;1:26-29. Russian.
Troshina EA, Rumyancev PO, Altashina MV, et al. [The overweight and obesity effect on breast cancer risk factors for postmenopausal women]. Ozhirenie i metabolizm. 2012;2:3-10. Russian.
Gershteyn ES, Kushlinskiy NE. [The growth factors, their receptors and underlying signal proteins: from an experiment to clinic]. Uspekhi molekulyarnoy onkologii. 2014;1:27-35. Russian.
Den’gina NV, Rodionov VV. [Radiation therapy of operable breast cancer after radical mastectomy: what, where, when?]. Prakticheskaya onkologiya. 2010;11(4):221-7. Russian.
Dobren’kiy MN, Dobren’kiy AM. [Molecular-biological and biochemical prognosis factors in breast cancer (literature overview)]. [Internet]. Available from: http://vestnik.rncrr.ru/vestnik/v5/papers/litdobr_v5.htm. Russian.
Bolotina LV, Zakiryakhodzhaev AD, Malygin SE, et al. [Clinical recommendations for the prevention, diagnostics and treatment of patients with breast cancer]. Moskva, OOO “Pechatnyy tsentr “Udacha”. 2014;47. Russian
Shchepotin IB,ZotovAS, Lubota RV, et al. [Clinical significance of p53 mutations in breast cancer (literature overview)]. Klinicheskaya onkologiya. 2012;8(4):1-4. Russian.
Komleva EO. [Molecular and genetical markers of tumor growth]. Sankt- Peterburg, Svetlitsa, 2010;148. Russian.
Krasil’nikov MA, Shcherbakov AM. [Signal pathways controlled by estrogens and their role in tumor progression: new facts and directions of search]. The successes of molecular oncology. 2014;1:18-26. Russian.
Lazukin AV. [The role of the Ki-67 marker in determining of the prognosis for breast cancer]. [Internet]. RMG. 2013;1. Available from: http://www.rmj.ru/articles/onkologiya/Roly_markera_Ki-67_v_opredelenii_prognoza_pri_rake_molochnoy_ghelezy/. Russian.
Perevodchikova NI, Stenina MB. (edit.) [Drug therapy for breast cancer]. Moskva, Praktika. 2014;284. Russian.
Lyubota RV. [The use of metformin in the treatment of breast cancer for patients with metabolic syndrome]. Tumors of the female reproductive system. 2015;11,4:18-24. Russian.
Tyulyandin SA, Nosov DA, Perevodchikova NI. (edit.) [Minimal clinical guidelines of the European Society of Medical Oncology (ESMO)]. Moskva, RONC Blokhina NN RAMN. 2010;436. Russian.
Semiglazov VF, Semiglazov VV, Manikhas AG, et al. [Neoadjuvant therapy of hormone-dependent breast cancer]. [Internet]. Available from: http://www.malignanttumors.org/jour/article/viewFile/21/25. Russian.
Novik AV,ZhabinaAS.[The importance of biomarkers for diagnosing and determining the treatment tactics of patients with tumors having unknown primary localization]. Prakticheskaya onkologiya. 2011;12,4:178-84. Russian.
Kosse VA, Bezruk NG, Ovsyannikov PV, Zavizion VF. [Breast cancer recurrences after organ-preserving treatment]. Vestnik problem biologii i meditsiny. 1999;1:119-22. Russian.
Taipov MA,KudryavtsevIA, Laktionov KP, et al. [The role of the cyclooxygenase-2 cascade in breast cancer metastasing]. Tumors of the female reproductive system. 2012;3-4:12-17. Russian.
Semiglazov VF,DashyanGA, Semiglazov VV. [Breast cancer endocrinotherapy: resistance overcoming]. [Internet]. Available from: http://umedp.ru/articles/endokrinoterapiya_raka_molochnoy_zhelezy_preodolenie_rezistentnosti.html. Russian.
SkvortsovVA, Manikhas GM. [Cyclin d1 and its prognostic significance in the planning of endocrine therapy for postmenopausal women with breast cancer]. [Internet]. Available from: http://vrach-aspirant.ru/articles/oncology/12031/. Russian.
KryachokIA, Gubareva AA, Aleksik EM et al. [Modern principles of adjuvant treatment for malignant neoplasms of the breast]. Klinicheskaya onkologiya. 2013;http://www.clinicaloncology.com.ua/article/magazine/14">2(10):118-22. Russian.
Teletaeva GM. [Basic principles of systemic therapy for luminal breast cancer (preoperative, adjuvant and palliative]. Prakticheskaya onkologiya. 2010;11(4):228-38. Russian.
Khisamov AA, Manuylova OO, Byakhov MYu. [Development mechanisms and ways to overcome endocrine resistance in breast cancer]. Malignant tumors. 2015;4:52-61. Russian.
Shushanov SS. [Insulin-like growth factor 1 type (IGF-1) and its receptor IGF-1R in regulation of differentiation and survival of normal and tumor cells]. [dissertation]. Moskva. 2015;48. Russian.
Brandão RD, Veeck J, Van de Vijver KK, et al. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Research. 2013;15:29. Available from: http://breast-cancer-research.com/content/15/2/R29].
Jirstrom K, Stendahl M, Ryden L, et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer. Res. 2005;65(17):80098016.
AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. ESO-ESMO 2-nd international consensus guidelines for advanced breast cancer, ABC2, 2014. Breast Care (Basel). 2015;10(3):199-205. doi:10.1159/000431248.
Al-Mansouri LJ, Alokail MS. Molecular basis of breast cancer. Saudi Med. J. 2006;27(1):9-16.
Henriksen KL, Sonne-Hansen K, Kirkegaard T, et al. Development of new predictive markers for endocrine therapy and resistance in breast cancer. Acta Oncologica. 2008;47(4):795-801.
Falandry C, Canney PA, Freyer G. Role of combination therapy with aromatase cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann. Oncol. 2009;20(4):615-20.
Zhu L, Chow LW, Loo WT, et al. Her2neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin. Cancer Res. 2004;10(14):4639-44.
Wilcken NR, Prall OW, Musgrove EA, et al. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res. 1997;3;849-54.
Regan MM, Price KN, Giobbie-Hurder A, et al. Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011;13:209. Available from: http://breast-cancer-research.com/content/13/3/209.
Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res. Treat. 2013;139(2):539-52. doi: 10.1007/s10549-013-2560-8.
Kheirandish Sh, Homaee F. Ki-67 protein: a proliferation index in breast cancer. Reviews Clin. Medicine. 2015:2,(4):205-8. doi: 10.17463/RCM.2015.04.010.
Ellis M, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-positive breast cancer. J. Clin. Oncol. 2001;19:3808-16.
NCCN Guidelines Version 2.2016 Invasive Breast Cancer.BINV-2 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf.
Kim HS, Yom CK, Kim HJ, et al. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Breast Cancer Res. Treat. 2010;121(3):777-88.
Fernandez-Cuesta L, Anaganti S, Hainaut P, et al. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Int. J. Cancer. 2010;128(8):1813-21.
Leo A, Cardoso F, Durbecq V, et al. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int. J. Clin. Oncol. 2002;7(4):245-53.
Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res. 2012;14(3):70. PMCID: PMC3446332.
Cuzick J, Dowsett M, Wale C, et al. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and the comparison with the GHI recurrence score—results from TransATAC. Cancer Res. 2009;69:503. doi: 10.1158/0008-5472.SABCS-09-74.
McShane L, Altman D, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 2005;23:9067-72.
Osborne CK, Bardou V, Hopp TA, et al. Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer. J. National Cancer Institute. 2003;95(5):353-61.
Ashok V, Dash C, Rohan TE, et al. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast. 2011;20(1):66-70.
Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin. Cancer Res. 2005;11(2):951-8.
De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin. Cancer Res. 2003;9:1039-46.
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2017 Medicni perspektivi (Medical perspectives)
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
